This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

Start Date01 Aug 2025

Sponsor / Collaborator

Duke University

[+1]

NCT06016517

/ Not yet recruitingNot ApplicableIIT

Application of the Personalized N-of-1 Trial Design in Patients with Rheumatoid Arthritis

The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are:
* What are the effects of different treatments on RA symptoms and condition for each individual patient
* What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study
Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life weekly (either in clinic or remotely) and report their level of pain daily (remotely).

Start Date15 May 2025

Sponsor / Collaborator

Tufts Medical Center, Inc.

ChiCTR2500101334

/ SuspendedPhase 4IIT

Efficacy and safety of Etanercept (Recombinant Human Tumor Necrosis Factor-a Receptor?:IgG Fc Fusion Protein for Injection) in the treatment of knee osteoarthritis

Start Date01 May 2025

Sponsor / Collaborator

The Second Affiliated Hospital of Xi'an Jiaotong University

100 Clinical Results associated with Etanercept

100 Translational Medicine associated with Etanercept

100 Patents (Medical) associated with Etanercept

8,441

Literatures (Medical) associated with Etanercept

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline

Article

Author: Zhang, Hanlin ; Wu, Chao ; Jin, Hongzhong

PURPOSE:

Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.

MATERIALS AND METHODS:

We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab. Upon admission, the patient presented with extensive, painful ulcerations on the trunk and extremities. He was started on oral methylprednisolone (32 mg/day) and minocycline (50 mg twice daily). After a week, minimal improvement was observed. After reviewing the screening results and discussing treatment options, the patient received two doses of spesolimab (900 mg intravenously) administered two weeks apart.

RESULTS:

Marked clinical improvement was observed after spesolimab initiation. Complete ulcer healing was achieved within six weeks of starting spesolimab, with no adverse effects reported.

CONCLUSIONS:

This case demonstrates the potential efficacy of spesolimab for treating refractory PG, particularly in patients unresponsive to TNF-α inhibitors. Despite the added complexity of the patient's underlying HBV infection and elevated M-protein, no HBV reactivation or other hematologic complications occurred. Further studies are needed to validate its role in managing PG and other neutrophilic dermatoses.

01 Jul 2025·JOURNAL OF NEUROIMMUNOLOGY

Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report

Article

Author: Marques, Rodolfo Francisco ; Lemos, Josemary Cavalcante ; Lana-Peixoto, Marco A ; Talim, Natalia ; Pedrosa, Denison Alves

We present the first reported case of central nervous system (CNS) demyelination associated with thalidomide. A 29-year-old female with a history of prurigo nodularis was prescribed thalidomide after the failure of other therapies. Three weeks later, she developed right hemiparesis and sensory disturbances in the right upper and lower extremities. Brain and spinal cord MRI showed hyperintense and gadolinium enhanced lesions. She was diagnosed with clinically isolated syndrome and treated with IV pulses of methylprednisolone with full recovery. Due to suspected association between her symptoms and thalidomide, the drug was discontinued. Three years later she returned to our Outpatient Clinic after being treated at another hospital for a new attack, characterized by muscle weakness and sensory disturbance in the lower limbs. Brain and spinal cord MRI showed new lesions, fulfilling the criteria for multiple sclerosis. We believe the association between thalidomide and CNS demyelination may be due to its tumor necrosis factor-α (TNF-α) inhibition effect. Biologic TNF-α inhibitors have been reported to cause CNS lesions, with cases of optic neuritis, transverse myelitis, multiple sclerosis, and neuromyelitis optica spectrum disorder developing after initiation of drugs such as etanercept, adalimumab, infliximab and golimumab. This report shows that thalidomide should be considered a potential cause of CNS demyelination, similar to biologic TNF-α inhibitors, and should be avoided in patients with a heightened risk.

01 Jul 2025·TOXICOLOGY AND APPLIED PHARMACOLOGY

Dual therapy for amanita phalloides-induced acute liver failure in mice: A combination of etanercept and alpha-1 antitrypsin

Article

Author: Suo, Huizhen ; Lichtinghagen, Ralf ; Wurm, Florian M ; Janciauskiene, Sabina ; Held, Julia ; Pino, Paco ; Hochnadel, Inga ; Kiseljak, Divor ; Wedemeyer, Hans Heinrich ; Jonigk, Danny ; Manns, Michael Peter ; Wurm, Maria J ; Yevsa, Tetyana ; Jedicke, Nils ; Petriv, Nataliia

BACKGROUND:

The toxin α-amanitin from Amanita phalloides induces hepatocyte death and disrupts local and systemic immune responses, key drivers of acute liver failure (ALF). Although TNF-α plays a central role in ALF, TNF-α-targeted therapies alone have shown limited efficacy.

METHODS:

Serum alpha1-globulin levels were measured retrospectively in a cohort of patients with amanita-induced ALF. Additionally, a murine interventional study was conducted, incorporating flow cytometry (FACS)-based immunophenotyping to analyze immune cell populations in the liver and lung to assess systemic versus liver-specific immune effects.

RESULTS:

We observed a correlation between lower serum alpha1-globulin levels-primarily comprising α1-antitrypsin (AAT)-and increased disease severity in patients with amanita-induced ALF. In a murine interventional study aiming to evaluate the therapeutic potential of alpha1-antitrypsin and TNF-α inhibition-alone and in combination-, the combined administration of etanercept (Enbrel®), a TNF-α scavenger, and recombinant AAT (recAAT) produced in CHO cells significantly improved survival rates in mice with amanita-induced ALF. Reduced liver damage markers, including lower cleaved caspase-3 levels, and decreased activation of liver CD4+ T cells and natural killer (NK) cells, accompanied this protective effect. Additionally, there was an increase in liver dendritic cells and IL-6+ TNF-α + macrophages, suggesting their potential role in mitigating liver injury. Immune changes in the lung were less pronounced and showed only modest reductions in CD4⁺ and NK1.1⁺ cells, with no significant shifts in innate immune populations.

CONCLUSIONS:

Our findings from the mouse model suggest a promising approach for treating ALF caused by α-amanitin from Amanita phalloides: the combined use of AAT (broad-spectrum protease inhibitor) and a TNF-α inhibitor. This dual therapy offers a novel and potentially effective treatment strategy for ALF patients.

240

News (Medical) associated with Etanercept

21 May 2025

·www.einpresswire.com

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence and quality of life [1-10] Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position in immunology and commitment to patient-centric innovation Basel, May 21, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the European launch of its Pyzchiva®* (ustekinumab) autoinjector.[1-2] This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung Bioepis, Pyzchiva® is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing over 60 kg.[1] The Pyzchiva® autoinjector supports a more comfortable self-administration experience [1-10] with accurate automatic dosing [1,3,4], less frequent injection pain [1,9,10], a compact design [1,3,4,6,7], and flexible storage options [1], offering the potential for improved adherence to patient treatment plans. Christophe Delenta, President Europe, Sandoz, said: “Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva® autoinjector, with its thoughtful and advanced features, addresses the real-world needs of patients in managing chronic inflammatory diseases. This launch marks another important milestone as we strengthen our leadership in immunology biosimilars and reaffirm our commitment to pioneering access across Europe’s evolving healthcare landscape.” Europe has the highest prevalence of psoriasis worldwide, affecting an estimated 6.4 million people.[11-13] Inflammatory bowel diseases, such as Crohn’s disease, are also common in Europe, affecting an estimated 2.5 to 3 million people.[14] Non-adherence to biologic therapies can lead to disease progression, increased flares and reduced quality of life, while contributing to increased healthcare utilization, including hospitalizations and additional treatments, thereby escalating healthcare costs.[15,16] Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across Europe. Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023. Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva® in Brazil, the US, the European Economic Area (EEA), Switzerland and the UK. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing and supply. ABOUT PYZCHIVA® (USTEKINUMAB) Pyzchiva® (ustekinumab) has been developed as a biosimilar with equivalent efficacy and comparable safety to the reference medicine Stelara®**, a human monoclonal antibody against interleukin (IL)-12/23. Pyzchiva® is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients six years and older weighing over 60 kg. The Pyzchiva® autoinjector is a pre-filled pen delivered through the Molly®*** platform of SHL Medical AG. It is available as a 90 mg in 1 mL autoinjector or a 45 mg in 0.5 mL autoinjector.[1,2] Pyzchiva® is also available as a 130mg concentrate in a vial for solution for infusion, a 90 mg and a 45 mg concentrate solution for injection in a pre-filled syringe. *Pyzchiva® is a trademark of Samsung Bioepis Co. Ltd. **Stelara® is a trademark of Johnson & Johnson ***Pyzchiva® will be delivered by SHL Medical’s patented Molly® technology. Molly® is a registered trademark of SHL Medical AG DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES [1] Pyzchiva® (ustekinumab) Summary of Product Characteristics. Available at: ema.europa.eu/en/documents/product-information/pyzchiva-epar-product-information_en.pdf (Accessed May 2025). [2] Samsung Bioepis. Data on file. [3] SHL Medical AG. Molly® autoinjector white paper. Available at: shl-medical.com/news-insights/downloads (Accessed May 2025). [4] SHL Medical AG. Molly® SE autoinjector letter. April 16, 2025. Data on file. [5] Paul C, Stalder JF, Thaçi D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol . 2012;26:448–455. [6] Tischer B, Mehl A. Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence . 2018;12:1413–1424. [7] Thakur K, Sandhu SK, Sharma A. Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. Rheumatol Ther . 2016;3:245–256. [8] Lopez A, Mounier M, Bouvier AM, et al.Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis . 2013;19:1528–1533. [9] Arendt-Nielsen L, Petersen-Felix S, Fischer M, Bak P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res . 2006;23:37–43. [10] Gill HS, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol . 2007;1:725–729. [11] International Federation of Psoriasis Associations (IFPA). Speaking up for psoriatic disease in Europe. Available at: ifpa-pso.com/content/tools/20072022_IFPA-FORUM_Briefing-Book_Speaking-up.pdf (Accessed May 2025). [12] Frede N, Gerdes S, Schön MP, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther . 2023;10:1655–1668. [13] Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther . 2013;7:201–210. [14] Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis . 2013;7:322–337. [15] Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther . 2015;32:983–1028. [16] Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases. Adv Ther . 2018;35:1333–1355. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. CONTACTS Global Media Relations Investor Relations Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com Alex Kalomparis +41 79 279 0285 Craig Marks +44 7818 942 383 Joerg E. Allgaeuer +49 171 838 4838 Rupreet Sandhu +41 79 410 5472 Attachment Media release_Pyzchiva autoinjector European launch.pdf Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalLicense out/inImmunotherapy

15 May 2025

·www.fiercepharma.com

Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit

Amgen is on the hook to pay Regeneron $135.6 million in compensatory damages and another $271.2 million in punitive damages, according to a jury verdict form filed Thursday. In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival.A federal jury in Delaware has determined that Amgen violated U.S. antitrust laws by engaging in a bundling scheme with pharma middlemen that unfairly advantaged its cholesterol-lowering drug Repatha over Regeneron’s PCSK9 counterpart Praluent.In turn, the jury has put Amgen on the hook to pay Regeneron $135.6 million in compensatory damages and another $271.2 million in punitive damages, according to a verdict form filed Thursday.“Since the FDA approved Praluent in 2015, Amgen has tried to remove and exclude Praluent from the market,” Joseph LaRosa, general counsel and secretary of Regeneron, said in a statement about the verdict.“After a failed patent litigation campaign, they pivoted toward an anticompetitive bundling scheme that created a dangerous precedent that virtually eliminated all competition,” he said, adding that the jury’s decision offers a “clear sign that anticompetitive efforts will not remain unchecked.”Amgen sees the situation differently and is naturally disappointed with the jury’s decision.“Amgen has always competed fairly and in compliance with the antitrust laws, and the trial made clear Regeneron had every opportunity to compete in the marketplace,” an Amgen spokesperson told Fierce Pharma over email, adding that the California drugmaker looks forward to post-trial proceedings.In civil cases, a judge may raise or reduce a jury’s damage award. The antitrust kerfuffle kicked off in May 2022 when Regeneron asserted in a lawsuit that Amgen had “sought by hook or crook” to exclude Praluent from the market and “entrench Repatha’s monopoly position.”The New York drugmaker specifically accused Amgen of tying rebates for Repatha to its unrelated and in-demand therapies Otezla and Enbrel, which are used to treat inflammatory conditions like arthritis and psoriasis. “When the value of these massive, unavoidable bundled rebates is compared to the cost of Repatha standing alone, it becomes clear that Amgen is pricing Repatha so that Regeneron cannot make a viable financial offer to compete,” Regeneron’s original lawsuit states.Amgen allegedly threatened to withhold those rebates unless pharmacy benefit managers preferred Repatha and excluded Praluent on their formularies. The move unfairly denied patients access to Praluent, Regeneron argued in a Thursday press release celebrating the jury verdict.Amgen attempted to get Regeneron’s lawsuit dismissed in August 2022, arguing in a motion at the time that Regeneron’s “allegations do not come close to meeting the standards required to state a claim” for antitrust violations.Amgen argued that Regeneron’s lawsuit was an effort to interfere with PBM competition, which has helped lower the price of Repatha and Praluent over the years. Meanwhile, this isn’t the only instance of Regeneron and Amgen duking it out over their PCSK9 drugs in court.Back in 2014, Amgen sued Sanofi and Regeneron over allegations that the partners’ drug Praluent—then in development as alirocumab—violated Amgen intellectual property tied to Repatha. After various twists and turns in appeals and ultimately the U.S. Supreme Court, Regeneron prevailed, with nine justices voting unanimously in May 2023 to uphold a lower court ruling invalidating a pair of Repatha patents.Praluent and Repatha won U.S. approvals just weeks apart in 2015. Both drugs work to help lower “bad” LDL cholesterol by blocking the protein PCSK9.

Patent InfringementDrug Approval

15 May 2025

·firstwordpharma.com

Amgen ordered to fork over $407M in Regeneron antitrust lawsuit

A federal jury in Delaware ordered Amgen on Thursday to pay Regeneron Pharmaceuticals nearly $407 million in damages for illegally bundling its cholesterol-lowering drug Repatha (evolocumab) with unrelated blockbuster medications to squeeze Regeneron's competing a PCSK9 blocker Praluent (alirocumab) out of the market.Regeneron filed the lawsuit in 2022. Amgen has denied the claims and argued that Regeneron's own business decisions were to blame for the decline in Praluent sales.Thursday's verdict includes $135.6 million in compensatory damages and $271.2 million in punitive damages.Jurors found that Amgen violated antitrust and tort laws by leveraging its anti-inflammatory drugs Enbrel (etanercept) and Otezla (apremilast) to persuade pharmacy benefit managers to select Repatha as the exclusive PCSK9 category product over Praluent, despite the medications treating entirely different conditions."Since the FDA approved Praluent in 2015, Amgen has tried to remove and exclude Praluent from the market," stated Joseph LaRosa, general counsel at Regeneron, in a company release. "After a failed patent litigation campaign, they pivoted toward an anticompetitive bundling scheme that created a dangerous precedent that virtually eliminated all competition."Regeneron earned $242 million from US sales of Praluent last year, while Amgen reported over $1.1 billion in US Repatha revenue."Fair competition is critical as it expands patient access to life-changing therapies and drives innovation forward," said Regeneron CEO Leonard Schleifer, adding that "larger companies should not be allowed to use anticompetitive tactics to push competitors out of the market."

Drug ApprovalPatent Infringement

100 Deals associated with Etanercept

External Link

KEGG	Wiki	ATC	Drug Bank
D00742	Etanercept	L04AB01	DB00005

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Psoriasis	China	C.H. Boehringer Sohn AG & Co. KG	26 Feb 2010
Non-radiographic axial spondyloarthritis	Australia	Pfizer Australia Pty Ltd.	18 Mar 2003
Polyarticular Juvenile Idiopathic Arthritis	United States	Immunex Corp.	15 Jan 2002
Ankylosing Spondylitis	European Union	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	Iceland	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	Liechtenstein	Pfizer Europe MA EEIG	02 Feb 2000
Ankylosing Spondylitis	Norway	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	European Union	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	Iceland	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	Liechtenstein	Pfizer Europe MA EEIG	02 Feb 2000
Arthritis, Psoriatic	Norway	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	European Union	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	Iceland	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	Liechtenstein	Pfizer Europe MA EEIG	02 Feb 2000
Axial Spondyloarthritis	Norway	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	European Union	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	Iceland	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	Liechtenstein	Pfizer Europe MA EEIG	02 Feb 2000
Enthesitis-Related Arthritis	Norway	Pfizer Europe MA EEIG	02 Feb 2000
Juvenile Idiopathic Arthritis	European Union	Pfizer Europe MA EEIG	02 Feb 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	United States	Amgen, Inc.	29 Nov 2016
Pain	Phase 3	Puerto Rico	Amgen, Inc.	29 Nov 2016
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Australia	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Belgium	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Colombia	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Czechia	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	France	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Germany	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Hungary	Pfizer Inc.	01 Sep 2009
Juvenile Pauciarticular Chronic Arthritis	Phase 3	Italy	Pfizer Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	-	-	Etanercept bio-originator	njvnsmlwpa(wqdysjowel) = 28% vs 22%, mostly injection site reactions zyjrboxvwv (pqibnbyxpz ) View more	-	05 Jun 2024
				Etanercept biosimilar SB4
EULAR2024	Not Applicable	Juvenile Idiopathic Arthritis First line	118	Etanercept (ETN)	eylcslrfll(pxpeohesai) = awwcjadxqk iwrftgfnwf (myauwxraio )	Positive	05 Jun 2024
				Adalimumab (ADA)	eylcslrfll(pxpeohesai) = yyakfnnayo iwrftgfnwf (myauwxraio )
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	sauljmkfbn(rflllwxrry) = ajxmkznrrc qlsgxxdlwp (juzmlgqpen )	Positive	05 Jun 2024
				Infliximab (IFX)	sauljmkfbn(rflllwxrry) = gdnnpmybuv qlsgxxdlwp (juzmlgqpen )
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Rituximab	ppoddakdvg(njrbkkalfq) = lnolfouivb cjcjwrnrea (qgnfxycdbc ) View more	-	05 Jun 2024
				Tocilizumab	ppoddakdvg(njrbkkalfq) = lureinxdtl cjcjwrnrea (qgnfxycdbc ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	biologic drugs (Obese patients)	btaazqvzru(iwwnbhtoke) = hredeplxvz hlonbeinpr (mpdkrtbqxw ) View more	Negative	05 Jun 2024
				biologic drugs (Non-obese patients)	btaazqvzru(iwwnbhtoke) = aabdlwgdac hlonbeinpr (mpdkrtbqxw ) View more
NCT02464878 (CTgov)	Phase 2	Diabetes Mellitus, Type 1	2	Islet Transplantation+Thymoglobulin+Basiliximab+Alpha 1-Antitrypsin+Etanercept	vlsdpoulve = imjphwbgog zqmrzzzwmt (viqvttymtq, nsuiyzonbo - egmpysqkei) View more	-	22 Dec 2023
ACR2023	Not Applicable	Spondylarthritis	-	Etanercept	ungjokqpdb(vudahrkskr) = hddkhocfmi ujfkbmugro (ckhbqfshda, 1.2 - 7.0)	Positive	14 Nov 2023
				Anti-TNF	ungjokqpdb(vudahrkskr) = qsraymtcdi ujfkbmugro (ckhbqfshda, 0.4 - 1.8)
NCT03636373 (CTgov)	Phase 4	Primary gout	5	Etanercept (Etanercept)	lqcfskfqhu(zhrwogfwix) = wnevktfxws ugtxpclzof (xpbqljpoaw, zhcwlcijpp - dnbcieezux) View more	-	27 Oct 2023
				Triamcinolone Acetonide (Triamcinolone Acetonide)	lqcfskfqhu(zhrwogfwix) = dzxrgydiey ugtxpclzof (xpbqljpoaw, wbkbsvzrvs - wtmywsqxyr) View more
FDA Manual	Not Applicable	Plaque psoriasis	211	Placebo	lbrwcvwswt(pyiebvxzho) = ffnvojonzt uzneaelkyu (llthixsxtp ) View more	Positive	18 Oct 2023
				Enbrel 0.8 mg/kg	lbrwcvwswt(pyiebvxzho) = cqezwhkeis uzneaelkyu (llthixsxtp ) View more
EULAR2023	Not Applicable	Arthritis, Psoriatic First line	-	Etanercept	cvzcjjtwag(juohmudyok) = epevkmxmcv lgzzeclisq (ozibjnzjye )	-	31 May 2023
				Monoclonal anti-TNF antibodies	cvzcjjtwag(juohmudyok) = adcnyzcliw lgzzeclisq (ozibjnzjye )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis